Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial.
Gryglas-Dworak A, Schim J, Ettrup A, Boserup LP, Josiassen MK, Ranc K, Sperling B, Ashina M. Gryglas-Dworak A, et al. Among authors: ettrup a. Headache. 2025 Jan;65(1):101-112. doi: 10.1111/head.14862. Epub 2024 Nov 5. Headache. 2025. PMID: 39501727 Free PMC article. Clinical Trial.
Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial.
Ashina M, Lipton RB, Ailani J, Versijpt J, Sacco S, Mitsikostas DD, Christoffersen CL, Sperling B, Ettrup A. Ashina M, et al. Among authors: ettrup a. Eur J Neurol. 2024 Feb;31(2):e16131. doi: 10.1111/ene.16131. Epub 2023 Nov 13. Eur J Neurol. 2024. PMID: 37955557 Free PMC article. Clinical Trial.
Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
Ailani J, McAllister P, Winner PK, Chakhava G, Josiassen MK, Lindsten A, Sperling B, Ettrup A, Cady R. Ailani J, et al. Among authors: ettrup a. BMC Neurol. 2023 Sep 6;23(1):318. doi: 10.1186/s12883-023-03368-3. BMC Neurol. 2023. PMID: 37674117 Free PMC article. No abstract available.
Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
Ashina M, Lanteri-Minet M, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B, Pozo-Rosich P. Ashina M, et al. Among authors: ettrup a. Cephalalgia. 2023 May;43(5):3331024231170807. doi: 10.1177/03331024231170807. Cephalalgia. 2023. PMID: 37125484 Free article. Clinical Trial.
Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study.
Barbanti P, Goadsby PJ, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B. Barbanti P, et al. Among authors: ettrup a. J Headache Pain. 2022 Dec 2;23(1):153. doi: 10.1186/s10194-022-01521-w. J Headache Pain. 2022. PMID: 36460983 Free PMC article. Clinical Trial.
68 results